GlassScriptPhysician profile
Farkhanda Khan
NPI 1548437668
$7,956.47
in general payments reported to CMS, 2019-2025
51 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 81% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $828 · 2020: $1,010 · 2021: $1,692 · 2022: $1,274 · 2023: $962 · 2024: $1,164 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,073.69 | 2019-2025 | |
| Ucb, INC. | $997.48 | 2019-2025 | Nayzilam, Briviact |
| Eisai INC. | $911.93 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $438.39 | 2020-2021 | |
| Pfizer INC. | $389.03 | 2023-2025 | |
| Lilly USA, LLC | $349.08 | 2019-2023 | Amyvid, Emgality, Reyvow |
| Harmony Biosciences LLC | $343.03 | 2020-2025 | Wakix |
| Sk Life Science, INC. | $274.50 | 2021-2025 | |
| Emd Serono, INC. | $269.30 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $255.86 | 2020-2025 | Ajovy, Austedo Xr, Austedo |
| Biogen, INC. | $255.42 | 2019-2025 | Vumerity, Tysabri |
| Biohaven Pharmaceutical Holding Company LTD. | $222.88 | 2022 | |
| Upsher-Smith Laboratories LLC | $214.12 | 2020-2022 | |
| Abbvie INC. | $201.80 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $172.61 | 2019-2024 | Rytary |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farkhanda Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.